千里光热激蛋白90-3(Hsp90-3)的生物信息学与功能分析

Hsp90是真核细胞重要的一类分子伴侣,与植物的生长发育、抗逆性、信号转导及生物进化等功能密切相关.为了深入理解高等植物Hsp90结构与功能的关系,该研究从千里光(Senecio scandens)全长cDNA文库中分离到Hsp90-3基因.序列分析结果表明,该基因编码699个氨基酸的多肽,与拟南芥(Arabidopsis thaliana)AtHsp90-3(登录号:NP_200412.1)的同源性最高,为93.71％;预测蛋白质的分子量为79.78 kD,理论等电点为5.08.信号序列分析结果发现,该蛋白主要定位于细胞的细胞核、过氧化物酶体、叶绿体类囊体膜及叶绿体基质中,提示作为分子伴侣,高等植物Hsp90-3参与细胞内膜系统蛋白质的转运.结构与功能分析发现,该蛋白有3个结构域及1个连接区,推测Hsp90-3在真核细胞的信号转导、转录调控及胁迫表达等过程中发挥重要功能.     

介导新生肽链折叠的胞质分子伴侣结构、功能及作用机制研究进展

分子伴侣是一类能够识别非天然蛋白并能协助其正确折叠、组装和转运的功能蛋白。最新研究发现,在原核或真核细胞中,不同结构、不同种类的分子伴侣形成了一个复杂的折叠系统,通过这个系统,蛋白质完成了从初步合成到形成具有生物活性的三维构象的过程,避免了折叠过程中多肽链的错误折叠、蛋白沉淀和有害物质的产生。文章综述了蛋白质折叠过程中不同种类分子伴侣组件的结构、功能和作用机制的研究进展,这些分子伴侣包括Hsp70、核糖体结合因子、伴侣素、前折叠素与Hsp90,并阐述了它们在蛋白质内稳态中的作用。     

副监护子CHIP与神经退行性疾病

CHIP属于连接酶类,具有E3泛素连接酶活性,参与能量代谢途径和新陈代谢。包括阿尔茨海默病(Alzheimer'sdisease,AD)、帕金森病(Parkinson'sdisease,PD)、亨廷顿病(Huntington'sdisease,HD)等在内的神经退行性疾病的主要病理学特征之一——细胞中异常蛋白的聚集,如tau蛋白和α-突触核蛋白等,副监护子CHIP与分子伴侣,如Hsc70/Hsp70、Hsp90等相互作用对这些异常蛋白的产生具有调节作用。最近研究表明,CHIP改变了Hsc70和Hsp90介导调节的信号通路中蛋白折叠和降解的平衡,参与细胞内蛋白质的质量控制;Hsp70/CHIP伴侣系统在tau蛋白生物学和tau蛋白病理学机制中具有重要作用;CHIP可以作为α-突触核蛋白蛋白酶体降解途径和溶酶体降解途径的分子开关。这些研究进展对于进一步揭示神经退行性疾病的发病机制和研制新一代治疗药物具有重要的作用。     

COP9信号复合体:信号转导与蛋白质降解的接合器

COP9信号复合体(CSN)是细胞内高度保守的多亚基蛋白质复合物,主要定位于真核细胞的细胞核。在结构上与26S蛋白酶体“盖子”亚复合物高度相关。CSN的具体功能目前尚未明确,主要体现为两方面的活性：脱Nedd化作用和磷酸化作用;在细胞内同SCF遍在蛋白连接酶复合体等许多蛋白质复合物发生相互作用;调节多种信号分子靶向遍在蛋白-26S蛋白酶体的稳定性。因此,CSN是连接信号转导与蛋白质降解的分子平台。     

热休克蛋白90在肝细胞癌中的研究进展

肝细胞癌中蛋白质稳态是其生长和转移的基础, Hsp90作为分子伴侣可维持多种促癌分子的稳定性,并抑制抑癌分子的活性,使蛋白质合成和降解之间保持平衡,致使癌细胞在恶劣微环境的持续刺激下依旧可以生存。然而, Hsp90抑制剂因在临床试验中表现出严重的不良反应,故迄今没有一种抑制剂获得FDA的批准。该篇文章阐述了Hsp90的结构、表达调控、伴侣循环以及Hsp90过表达与肝细胞癌之间的联系,旨在阐明Hsp90在肝细胞癌发生发展中的作用,为临床用药提供理论依据。     

小鼠精子热休克蛋白90的棕榈酰化

蛋白质棕榈酰化是指饱和十六碳的棕榈酸盐通过硫酯键或者酰胺键连接在蛋白质肽链的半胱氨酸上,属翻译后修饰,可影响蛋白质的相互作用、稳定性及定位等功能。热休克蛋白90(heat shock protein 90,Hsp90)是一种重要的分子伴侣,已证明其参与精子获能等生理过程。然而,哺乳动物精子中是否存在蛋白质棕榈酰化,Hsp90在精子不同生理状态下是否发生棕榈酰化,目前尚不清楚。本研究首先采用酰基-生物素置换法检测小鼠附睾尾部成熟精子总蛋白质棕榈酰化情况,然后通过CSS-Palm 4.0软件预测Hsp90的棕榈酰化位点,再进一步结合免疫沉淀方法检测附睾头部、附睾尾部精子的Hsp90棕榈酰化情况。结果显示,小鼠附睾尾部精子多种蛋白质存在棕榈酰化,其中分子量大小约50、65、72、85和130 k Da的蛋白质发生棕榈酰化最为显著;软件预测显示Hsp90两个亚型共有5个棕榈酰化位点;免疫沉淀结果也显示小鼠精子存在棕榈酰化的Hsp90,且其棕榈酰化水平与小鼠精子的生理状态有关:附睾尾部棕榈酰化水平比附睾头部高,而获能后的棕榈酰化水平比获能前明显升高。以上结果表明,哺乳动物精子中存在蛋白棕榈酰化,且Hsp90棕榈酰化可能参与精子生理状态的调节。     

TPR蛋白对Hsp90功能的调节

热激蛋白Hsp90是一类在进化中形成的高度保守的且可参与多种细胞功能的特异分子伴侣。TPR蛋白通常存在于Hsp90的多蛋白质复合物中,它对Hsp90的功能的多样性起着至关重要的作用,同时Hsp90可能为TPR蛋白提供“泊位”,允许不同的TPR蛋白在Hsp90分子伴侣底物附近有序而特异结合,从而使Hsp90在细胞内环境中以特定的方式完成其各种细胞功能。了解TPR蛋白与Hsp90的相互作用机制为阐明细胞内Hsp90的功能多样性和特异性奠定了基础。     

真菌Hsp90研究进展

近年来,随着广谱抗生素、化疗以及器官移植技术的广泛应用,真菌感染日益严重,从分子水平揭示病原真菌的致病机制对真菌感染的防控、治疗至关重要。微生物适应宿主微环境压力的能力在其共生与感染过程中发挥着关键作用,heat shock protein 90（Hsp90）是真核生物参与压力应答响应的分子伴侣,它不仅参与胞内蛋白质的折叠,还与许多底物蛋白相互作用共同调节病原真菌的形态发育、生物被膜形成、有性生殖、毒力以及耐药性。本文从真菌Hsp90的活性调节、底物蛋白,以及Hsp90与病原真菌形态发生、有性生殖、耐药性调控等方面综述了近年来真菌Hsp90信号通路的研究进展。     

辅助伴侣分子Cdc37蛋白的研究进展

细胞分裂周期蛋白Cdc37最初是在芽殖酵母中发现的细胞周期相关蛋白。随后的研究表明Cdc37具有伴侣分子活性,可以特异地募集一系列的蛋白激酶结合到热激蛋白90（Hsp90）上,形成特定的分子伴侣复合体,参与维持蛋白的稳定性和激酶活性。Cdc37参与了细胞内的多项生命活动,在细胞周期、信号转导和基因表达中都起着重要的作用。由于Cdc37在肿瘤组织中特异性地高表达,使其成为肿瘤治疗中一个重要的分子靶点。     

Hsp70在神经退行性疾病中的作用机制研究进展

热休克蛋白Hsp70 (heat shock protein 70, Hsp70)是一类广泛存在的分子伴侣。阿尔茨海默病(Alzheimer’s disease)、帕金森病(Parkinson’s disease)等神经退行性疾病共同的病理特征是错误折叠的蛋白质(包括Tau、α-突触核蛋白、TDP-43、朊蛋白和多聚谷氨酰胺蛋白)形成有毒性的寡聚体或淀粉样纤维。大量的研究表明,Hsp70可以调控这些蛋白质的代谢进程,包括将错误折叠的蛋白质重折叠、抑制蛋白质聚集以及降解错误折叠的蛋白质。Hsp70在发挥功能时需要相对应的辅助分子伴侣的帮助。该文详细论述了Hsp70抑制Tau蛋白病、α-突触核蛋白病、TDP-43蛋白病、传染性海绵状脑病以及多聚谷氨酰胺疾病的作用机制,重点阐述了Hsp70对神经退行性疾病中错误折叠蛋白质聚集和毒性的抑制作用,并讨论和展望了Hsp70在神经退行性疾病的治疗中存在的挑战和机遇。     

The mammalian CHORD-containing protein melusin is a stress response protein interacting with Hsp90 and Sgt1

Melusin is a mammalian muscle specific CHORD containing protein capable of activating signal transduction pathways leading to cardiomyocytes hypertrophy in response to mechanical stress. To define melusin function we searched for molecular partners possibly involved in melusin dependent signal transduction. Here we show that melusin and heat shock proteins are co-regulated. Moreover, melusin directly binds to Hsp90, a ubiquitous chaperone involved in regulating several signaling pathways. In addition, melusin interacts with Sgt1, an Hsp90 binding molecule. Melusin does not behave as an Hsp90 substrate but rather as a chaperone capable to protect citrate synthase from heat induced aggregation. These results describe melusin as a new component of the Hsp90 chaperone machinery.     

The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention

Signal transduction mediated by ErbB/HER receptor tyrosine kinases is crucial for the development and maintenance of epithelial tissues, and aberrant signaling is frequently associated with malignancies of epithelial origin. This review focuses on the roles played by the Hsp90 chaperone machinery in the regulation of signaling through the ErbB/HER network, and discusses potential therapeutic strategies that disrupt chaperone functions. Hsp90 and its associated cochaperones regulate ErbB signal transduction through multiple mechanisms. The chaperone system controls the stability of the nascent forms of both ErbB-1 (EGF-receptor) and ErbB-2/HER2, while regulation of the mature form is restricted to ErbB-2. Regulation by the Hsp90 complex extends to downstream effectors of ErbB signaling, namely Raf-1, Pdk-1 and Akt/PKB. Disrupting the function of Hsp90 results in the degradation of both the receptors and their effectors, thereby inhibiting tumor cell growth. The importance of an Hsp90-recognition motif located within the kinase domain of ErbB-2 is discussed, as well as a direct role for Hsp90 in regulating tyrosine kinase activity. In light of recent observations, we emphasize the ability of specific tyrosine kinase inhibitors to selectively target ErbB-2 to the chaperone-mediated degradation pathway. ErbB-specific drugs are already used to treat cancers, and clinical trials are underway for additional compounds that intercept ErbB signaling, including drugs that target Hsp90. Hence, the dependence of ErbB-2 upon Hsp90 reveals an Achilles heel, which opens a window of opportunity for combating cancers driven by the ErbB/HER signaling network.     

The Achilles Heel of ErbB-2/HER2: Regulation by the Hsp90 Chaperone Machine and Potential for Pharmacological Intervention

Signal transduction mediated by ErbB/HER receptor tyrosine kinases is crucial for the development and maintenance of epithelial tissues, and aberrant signaling is frequently associated with malignancies of epithelial origin. This review focuses on the roles played by the Hsp90 chaperone machinery in the regulation of signaling through the ErbB/HER network, and discusses potential therapeutic strategies that disrupt chaperone functions. Hsp90 and its associated co-chaperones regulate ErbB signal transduction through multiple mechanisms. The chaperone system controls the stability of the nascent forms of both ErbB-1 (EGF-receptor) and ErbB-2/HER2, while regulation of the mature form is restricted to ErbB-2. Regulation by the Hsp90 complex extends to downstream effectors of ErbB signaling, namely Raf-1, Pdk-1 and Akt/PKB. Disrupting the function of Hsp90 results in the degradation of both the receptors and their effectors, thereby inhibiting tumor cell growth. The importance of an Hsp90-recognition motif located within the kinase domain of ErbB-2 is discussed, as well as a direct role for Hsp90 in regulating tyrosine kinase activity. In light of recent observations, we emphasize the ability of specific tyrosine kinase inhibitors to selectively target ErbB-2 to the chaperone-mediated degradation pathway. ErbB-specific drugs are already used to treat cancers, and clinical trials are underway for additional compounds that intercept ErbB signaling, including drugs that target Hsp90. Hence, the dependence of ErbB-2 upon Hsp90 reveals an Achilles heel, which opens a window of opportunity for combating cancers driven by the ErbB/HER signaling network.     

Modulation of heme/substrate binding cleft of neuronal nitric-oxide synthase (nNOS) regulates binding of Hsp90 and Hsp70 proteins and nNOS ubiquitination

Like other nitric-oxide synthase (NOS) enzymes, neuronal NOS (nNOS) turnover and activity are regulated by the Hsp90/Hsp70-based chaperone machinery, which regulates signaling proteins by modulating ligand binding clefts (Pratt, W. B., Morishima, Y., and Osawa, Y. (2008) J. Biol. Chem. 283, 22885-22889). We have previously shown that nNOS turnover is due to Hsp70/CHIP-dependent ubiquitination and proteasomal degradation. In this work, we use an intracellular cross-linking approach to study both chaperone binding and nNOS ubiquitination in intact HEK293 cells. Treatment of cells with N(G)-nitro-L-arginine, a slowly reversible competitive inhibitor that stabilizes nNOS, decreases both nNOS ubiquitination and binding of Hsp90, Hsp70, and CHIP. Treatment with the calcium ionophore A23187, which increases Ca(2+)-calmodulin binding to nNOS, increases nNOS ubiquitination and binding of Hsp90, Hsp70, and CHIP in a manner that is specific for changes in the heme/substrate binding cleft. Both Hsp90 and Hsp70 are bound to the expressed nNOS oxygenase domain, which contains the heme/substrate binding cleft, but not to the reductase domain, and binding is increased to an expressed fragment containing both the oxygenase domain and the calmodulin binding site. Overexpression of Hsp70 promotes nNOS ubiquitination and decreases nNOS protein, and overexpression of Hsp90 inhibits nNOS ubiquitination and increases nNOS protein, showing the opposing effects of the two chaperones as they participate in nNOS quality control in the cell. These observations support the notion that changes in the state of the heme/substrate binding cleft affect chaperone binding and thus nNOS ubiquitination.     

Hsp90 recognizes a common surface on client kinases

Hsp90 is a highly abundant chaperone whose clientele includes hundreds of cellular proteins, many of which are central players in key signal transduction pathways and the majority of which are protein kinases. In light of the variety of Hsp90 clientele, the mechanism of selectivity of the chaperone toward its client proteins is a major open question. Focusing on human kinases, we have demonstrated that the chaperone recognizes a common surface in the amino-terminal lobe of kinases from diverse families, including two newly identified clients, NFkappaB-inducing kinase and death-associated protein kinase, and the oncoprotein HER2/ErbB-2. Surface electrostatics determine the interaction with the Hsp90 chaperone complex such that introduction of a negative charge within this region disrupts recognition. Compiling information on the Hsp90 dependence of 105 protein kinases, including 16 kinases whose relationship to Hsp90 is first examined in this study, reveals that surface features, rather than a contiguous amino acid sequence, define the capacity of the Hsp90 chaperone machine to recognize client kinases. Analyzing Hsp90 regulation of two major signaling cascades, the mitogen-activated protein kinase and phosphatidylinositol 3-kinase, leads us to propose that the selectivity of the chaperone to specific kinases is functional, namely that Hsp90 controls kinases that function as hubs integrating multiple inputs. These lessons bear significance to pharmacological attempts to target the chaperone in human pathologies, such as cancer.